Not all insurance types use copay accumulators. Medicare and Medicaid prohibit copay assistance because federal anti-kickback ...

The competing strategies of patient assistance programs and co-pay accumulator adjustment programs create confusion and administrative burden for clinicians and patients, potentially reducing ...

When Gury Doshi, MD, learned that a patient’s insurance didn’t cover her breast cancer medication, Doshi had a potential workaround. The patient could try to bypass the insurer and access the drug at ...

Anna Sutton was shocked when she received a letter from her husband’s job-based health plan stating that Humira, an expensive drug used to treat her daughter’s juvenile arthritis, was now on a long ...

Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting ...

Why do pharmaceutical companies charge exorbitant rates for their products but then give them away for free or virtually no cost to most patients, regardless of income, through patient assistance ...

Drug company–sponsored pharmacy assistance programs (PAPs) are an imperfect solution to a wide-ranging access problem. These programs help millions of people with chronic conditions get life-saving ...

On this Ropes & Gray podcast, health care partner Michael Lampert and counsel Sam Perrone, and litigation & enforcement partner Andrew O’Connor, rejoin to discuss patient assistance programs, recent ...

Associations of Financial Hardship and Health Status, Social Functioning, and Mental Health Among Cancer Survivors in the United States: Findings From a Nationally Representative Study Ulman ...

In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters. In the early 1990’s, during the debate over the ...

Imatinib was the first targeted therapy approved for the treatment of cancer. With its approval, it was immediately clear to Novartis that this breakthrough therapy would require an innovative ...